An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease on Hemodialysis (GIFT-R)
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2016
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms GIFT-R
- Sponsors AbbVie
- 02 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Aug 2016 Planned initiation date changed from 1 Jul 2016 to 1 Sep 2016.
- 24 Aug 2016 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.